RESUMEN
PURPOSE: This cross-sectional study aimed at comparing the quality of life (Qol), the prevalence of psychiatric diagnosis and pharmacological treatment in 104 candidates to bariatric surgery according to the degree of obesity (class 2 vs. class ≥ 3 obesity). METHODS: All surgical candidates underwent a detailed psychiatric interview based on DSM-5 criteria, including sociodemographic, clinical, psychological and psychiatric data. Participants completed the Binge Eating Scale (BES) and the 12-Item Short Form Health Survey (SF-12). RESULTS: Overall, bariatric candidates reported a significant impairment in the physical (PCS 38.8 [95% CI 36.2-41.5]) and mental (MCS 42.2 [95% CI 40.4-43.9]) components of Qol compared to population norms (p < 0.001 for both). Subjects with class 2 obesity scored significantly lower in the MCS compared to those with class 3 (38.7 (8.1) vs. 43.6 (8.4), p = 0.008). No other statistically significant differences were found between the two groups in terms of sociodemographic and clinical variables. CONCLUSION: These data support the usefulness of Qol assessment in bariatric candidates as a sensible screening parameter, especially in patients with lower BMI, in whom MCS could identify the need for early psychosocial intervention. LEVEL OF EVIDENCE: Level III, case-control analytic study.
Asunto(s)
Cirugía Bariátrica , Trastornos Mentales , Obesidad Mórbida , Índice de Masa Corporal , Estudios Transversales , Humanos , Calidad de VidaRESUMEN
The medium-term (16 weeks) effects of the combination of captopril and hydrochlorothiazide (HCTZ) on some metabolic indexes, particularly on plasma lipoproteins, were evaluated in 20 mild to moderate hypertensive outpatients. After a 4-week wash-out period, the subjects were given one tablet of a new commercially available fixed combination once/daily (i.e., captopril 50 mg + HCTZ 25 mg). The dose could be titrated to a maximum of one tablet twice daily according to individual blood pressure responses. Both systolic and diastolic blood pressure significantly decreased at week 4 and showed a further decrease thereafter; the rate of responders (diastolic blood pressure at or below 90 mm Hg at the end of the study) was very high (90%). The only metabolic change was a small though significant increase in HDL cholesterol (P less than .05), almost entirely due to an increase in the denser HDL3 subfraction. The atherogenic fractions, namely total cholesterol, LDL cholesterol, and apoprotein B, showed no significant changes. Plasma triglycerides underwent a transient increase at week 8 (P less than .05) but thereafter fell. Plasma glucose, creatinine, uric acid, and potassium were unchanged. The fixed combination of captopril and HCTZ seems highly effective in lowering blood pressure and seems devoid of untoward metabolic effects. Its overall impact on the coronary risk profile in hypertensive subjects seems therefore to be favorable.
Asunto(s)
Presión Sanguínea/efectos de los fármacos , Captopril/farmacología , Hidroclorotiazida/farmacología , Hipertensión/sangre , Lipoproteínas/sangre , Adulto , Anciano , Captopril/administración & dosificación , Captopril/uso terapéutico , Diástole , Quimioterapia Combinada , Femenino , Humanos , Hidroclorotiazida/administración & dosificación , Hidroclorotiazida/uso terapéutico , Hipertensión/tratamiento farmacológico , Masculino , Persona de Mediana Edad , SístoleRESUMEN
The effect of fructose-1,6-diphosphate (FDP) on left ventricular function was assessed in seven patients with chronic ischemic heart disease and eight patients with idiopathic dilated cardiomyopathy. In a crossover study design each patient received 10 gm of FDP or saline placebo intravenously for three days. An M-mode echocardiographic assessment of left ventricular (LV) function was made before and after each treatment period. After FDP treatment, LV end-diastolic and systolic dimensions showed a 6% reduction (P less than 0.01), while peak lengthening rate of LV dimension in diastole and peak shortening rate of LV dimension in systole increased 17% and 10%, respectively (P less than 0.05). There was evidence that FDP was more effective in the patients with ischemic heart disease than in the patients with cardiomyopathy.
Asunto(s)
Fructosadifosfatos/uso terapéutico , Corazón/efectos de los fármacos , Hexosadifosfatos/uso terapéutico , Anciano , Cardiomegalia/tratamiento farmacológico , Cardiomiopatía Dilatada/tratamiento farmacológico , Cardiomiopatía Dilatada/fisiopatología , Enfermedad Crónica , Ensayos Clínicos como Asunto , Enfermedad Coronaria/tratamiento farmacológico , Enfermedad Coronaria/fisiopatología , Ecocardiografía , Femenino , Fructosadifosfatos/farmacología , Corazón/fisiopatología , Ventrículos Cardíacos/efectos de los fármacos , Ventrículos Cardíacos/fisiopatología , Humanos , Masculino , Persona de Mediana EdadRESUMEN
The effects of enalapril on plasma lipoproteins were evaluated in an open study of 12 normolipidemic outpatients with mild-to-moderate essential hypertension (World Health Organization stages I and II). After a two-week washout period, during which placebo was given, the patients received 20 to 40 mg/day of enalapril for 16 weeks. Treatment with enalapril was associated with significant increases in levels of HDL cholesterol (mean, 23%; P less than 0.001) and apoprotein A (mean, 11%; P less than 0.01), largely because of the increase in the subfraction HDL2 (mean, 43%; P less than 0.001), although the subfraction HDL3 also rose (mean, 14%; P less than 0.005). Total cholesterol and LDL cholesterol levels did not change, whereas triglycerides decreased significantly (mean, 26%; P less than 0.001). Apoprotein B was unchanged. Unlike diuretics and most beta-blockers, enalapril favorably affects plasma lipoprotein levels, thus improving the overall cardiovascular risk in hypertensive patients.
Asunto(s)
HDL-Colesterol/sangre , Enalapril/farmacología , Hipertensión/sangre , Adulto , Apolipoproteínas A/sangre , Enalapril/administración & dosificación , Femenino , Humanos , Hipertensión/tratamiento farmacológico , Masculino , Persona de Mediana EdadRESUMEN
Platelet alpha-2-adrenergic receptor number and affinity were examined in 12 patients with class IV NYHA congestive heart failure (CHF) and 10 normal volunteers paired for age and sex. Platelet alpha-2-adrenergic receptor number is significantly decreased in CHF patients (178 +/- 18 fmol/mg prot. vs 282 +/- 21 fmol/mg prot. p less than 0.05). After Captopril treatment (6 weeks) alpha-2-receptor number increased but this increase was not statistically significant (236 +/- 28 fmol/mg prot.). This study supports the hypothesis that increased levels of circulating catecholamines in CHF lead to a decrease in platelet alpha-2-adrenoreceptors. Improved cardiac function following administration of Captopril could lead to a withdrawal of sympathetic tone. Captopril may also interact with sympathetic nervous function.
Asunto(s)
Plaquetas , Captopril/uso terapéutico , Insuficiencia Cardíaca/fisiopatología , Receptores Adrenérgicos alfa/análisis , Anciano , Captopril/administración & dosificación , Captopril/farmacología , Femenino , Insuficiencia Cardíaca/sangre , Insuficiencia Cardíaca/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Receptores Adrenérgicos alfa/efectos de los fármacos , Receptores Adrenérgicos alfa/fisiología , Factores de TiempoAsunto(s)
Bloqueadores de los Canales de Calcio/farmacología , Deformación Eritrocítica/efectos de los fármacos , Adulto , Anciano , Ensayos Clínicos como Asunto , Método Doble Ciego , Femenino , Humanos , Hipertensión/sangre , Hipertensión/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Nifedipino/farmacología , Nifedipino/uso terapéutico , Propilaminas/farmacología , Propilaminas/uso terapéutico , Distribución Aleatoria , Clorhidrato de TiapamiloRESUMEN
The effects of two different calcium-channel blocking agents on platelet alpha-2 adrenoceptors were studied in 18 mild to moderate hypertensive patients. The subjects were randomly assigned in a double blind fashion to treatment with either nifedipine 10 mg t.i.d. or tiapamil 300 b.i.d. for six weeks. Platelet alpha-2 receptors were studied before and following 6 weeks of treatment using radioligand binding assay (3H Rauwolscine). Both agents induced a reduction in alpha-2 receptors, which reached statistical significance only for nifedipine. Such a reduction may contribute to the antihypertensive effect of calcium-channel blocking drugs.
Asunto(s)
Plaquetas/metabolismo , Bloqueadores de los Canales de Calcio/farmacología , Hipertensión/sangre , Receptores Adrenérgicos alfa/metabolismo , Adulto , Anciano , Plaquetas/efectos de los fármacos , Bloqueadores de los Canales de Calcio/uso terapéutico , Femenino , Humanos , Hipertensión/tratamiento farmacológico , Masculino , Persona de Mediana EdadRESUMEN
OBJECTIVE: To estimate the relationship between structural changes in the heart and in the carotid arteries in hypertensives and to analyze the correlations between these structural changes and cardiovascular risk factors. METHODS: We studied 76 subjects (39 men and 27 women, mean age 45+/-7 years) with mild-to-moderate untreated and uncomplicated hypertension. All of the subjects underwent ambulatory blood pressure monitoring, M-mode echocardiography for evaluation of their left ventricular mass and B-mode high-resolution ultrasonography to determine their carotid arterial wall thickness. RESULTS: The mean intimal plus medial thickness of the common carotid artery was found to be related significantly and independently to the left ventricular mass indexed by the body surface area. In multivariate analysis, age and the high-density lipoprotein cholesterol level were related strongly to the intimal plus medial thickness, whereas the clinic systolic blood pressure, average night-time systolic blood pressure and glycemia were the most important determinants of the left ventricular mass index. Logistic regression analysis suggested that the thickness of the posterior left ventricular wall was a stronger predictor of the carotid intima-medial thickness than were age and the high-density lipoprotein cholesterol level. CONCLUSION: The carotid wall thickness and left ventricular mass of hypertensives are related independently; nevertheless the main determinants of structural cardiac and vascular changes are probably different.